NUTRA PHARMA CORP.: operating income or loss
Operating income or loss for NUTRA PHARMA CORP. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All NUTRA PHARMA CORP. financial histories
What this measure means
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
Exact concept: us-gaap:OperatingIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -1,462,338 | USD | 2026-05-20 | 10-K · 0001493152-26-024641 |
| 2024-01-01 | 2024-12-31 | -878,421 | USD | 2026-05-20 | 10-K · 0001493152-26-024641 |
| 2023-01-01 | 2023-12-31 | -886,979 | USD | 2026-02-17 | 10-K · 0001493152-26-007044 |
| 2022-01-01 | 2022-12-31 | -1,907,404 | USD | 2025-11-24 | 10-K · 0001493152-25-024800 |
| 2021-01-01 | 2021-12-31 | -1,988,445 | USD | 2025-09-03 | 10-K · 0001641172-25-026446 |
| 2020-01-01 | 2020-12-31 | -924,947 | USD | 2022-04-15 | 10-K · 0001493152-22-010035 |
| 2019-01-01 | 2019-12-31 | -1,229,893 | USD | 2021-09-08 | 10-K · 0001493152-21-022204 |
| 2018-01-01 | 2018-12-31 | -1,878,862 | USD | 2021-07-01 | 10-K · 0001493152-21-015860 |
| 2017-01-01 | 2017-12-31 | -1,381,940 | USD | 2021-02-05 | 10-K · 0001398432-21-000007 |
| 2016-01-01 | 2016-12-31 | -2,043,516 | USD | 2018-04-17 | 10-K · 0001398432-18-000049 |
| 2015-01-01 | 2015-12-31 | -5,766,133 | USD | 2017-04-17 | 10-K · 0001398432-17-000073 |
| 2014-01-01 | 2014-12-31 | -2,202,274 | USD | 2016-04-14 | 10-K · 0001398432-16-000597 |
| 2013-01-01 | 2013-12-31 | -2,361,438 | USD | 2015-04-13 | 10-K · 0001398432-15-000168 |
| 2012-01-01 | 2012-12-31 | -2,601,099 | USD | 2014-03-31 | 10-K · 0001144204-14-019555 |
| 2011-01-01 | 2011-12-31 | -3,950,583 | USD | 2013-04-16 | 10-K · 0001144204-13-022247 |
| 2010-01-01 | 2010-12-31 | -3,396,443 | USD | 2012-11-15 | 10-K/A · 0001144204-12-063254 |
Related financial histories
- NUTRA PHARMA CORP.: total assets
- NUTRA PHARMA CORP.: total liabilities
- NUTRA PHARMA CORP.: stockholders equity
- NUTRA PHARMA CORP.: cash and cash equivalents
- NUTRA PHARMA CORP.: net income or loss
- NUTRA PHARMA CORP.: operating cash flow
- NUTRA PHARMA CORP.: capital expenditure payments
- NUTRA PHARMA CORP.: revenue
- NUTRA PHARMA CORP.: contract revenue excluding tax
- NUTRA PHARMA CORP.: financing cash flow
- NUTRA PHARMA CORP.: investing cash flow
- NUTRA PHARMA CORP.: retained earnings or deficit
- NUTRA PHARMA CORP.: basic weighted-average shares
- NUTRA PHARMA CORP.: diluted weighted-average shares
- NUTRA PHARMA CORP.: basic earnings per share
- NUTRA PHARMA CORP.: diluted earnings per share
- NUTRA PHARMA CORP.: net property, plant and equipment
- NUTRA PHARMA CORP.: share-based compensation expense
- NUTRA PHARMA CORP.: current assets
- NUTRA PHARMA CORP.: interest expense
- NUTRA PHARMA CORP.: current liabilities
- NUTRA PHARMA CORP.: current accounts payable
- NUTRA PHARMA CORP.: net current accounts receivable
- NUTRA PHARMA CORP.: operating expenses
- NUTRA PHARMA CORP.: net inventory
- NUTRA PHARMA CORP.: gross profit
- NUTRA PHARMA CORP.: selling, general and administrative expense
- NUTRA PHARMA CORP.: research and development expense
Inspect the source
- Entity
- NUTRA PHARMA CORP. / CIK 0001119643
- Captured
- 2026-09-20T05:24:45.365Z
- SEC response SHA-256
a9ccf17d1b07544de23a6dd72641e83d2b0b8f34b5c47b58fd5a236f1c887339
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001119643.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))